Stock futures slid on Wednesday after June inflation data came in hotter-than-expected, contributing to growing fears that the Federal Reserve will get more aggressive in its fight to tame rising prices.
•$Humanigen (HGEN.US)$-65.2% (receives preliminary topline data from NIH/NIAID study of Lenzilumab in ACTIV-5/BET-B ; study did not meet primary endpoint)